Maridebart Cafraglutide
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Amgen · Phase 3 · Recruiting · Enrollment 3200
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Maridebart Cafraglutide Low Dose Q4W | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide Medium Dose Q4W | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide Medium Dose Q8W | n/r | n/r | n/r | n/r |
| Placebo Q4W (Received Medium Dose Maridebart Cafraglutide in Parent Trial) | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide High Dose Q4W | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide High Dose Q8W | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide High Dose Q12W | n/r | n/r | n/r | n/r |
| Placebo Q4W (Received High Dose Maridebart Cafraglutide in Parent Trial) | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide High Dose Q4W (Received Placebo in the Parent Trial) | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide Low Dose Q4W(Received Very Low Dose Maridebart Cafraglutide in Parent Trial) | n/r | n/r | n/r | n/r |
Not shown
- Maridebart Cafraglutide Low Dose Q4W: endpoint not reported
- Maridebart Cafraglutide Medium Dose Q4W: endpoint not reported
- Maridebart Cafraglutide Medium Dose Q8W: endpoint not reported
- Placebo Q4W (Received Medium Dose Maridebart Cafraglutide in Parent Trial): endpoint not reported
- Maridebart Cafraglutide High Dose Q4W: endpoint not reported
- Maridebart Cafraglutide High Dose Q8W: endpoint not reported
- Maridebart Cafraglutide High Dose Q12W: endpoint not reported
- Placebo Q4W (Received High Dose Maridebart Cafraglutide in Parent Trial): endpoint not reported
- Maridebart Cafraglutide High Dose Q4W (Received Placebo in the Parent Trial): endpoint not reported
- Maridebart Cafraglutide Low Dose Q4W(Received Very Low Dose Maridebart Cafraglutide in Parent Trial): endpoint not reported